NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today…
https://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.png00Storm Charbonneauhttps://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.pngStorm Charbonneau2021-03-25 21:03:092021-03-25 21:03:15Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
March 23, 2021 07:30 AM Eastern Daylight Time
NEW YORK & CHICAGO--(BUSINESS WIRE)--Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose…
https://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.png00Storm Charbonneauhttps://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.pngStorm Charbonneau2021-03-23 16:15:042021-03-23 16:15:08Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today…
https://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.png00Storm Charbonneauhttps://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.pngStorm Charbonneau2021-03-18 16:42:592021-03-18 16:43:05EYENOVIA TO REPORT FOURTH QUARTER AND FULL YEAR 2020 RESULTS ON THURSDAY, MARCH 25
NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology,…
https://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.png00Storm Charbonneauhttps://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.pngStorm Charbonneau2021-03-10 21:30:572021-03-10 21:31:02Eyenovia to Participate in the 33rd Annual Roth Conference
March 02, 2021 07:30 AM Eastern Standard Time
NEW YORK--(BUSINESS WIRE)--Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced…
https://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.png00Storm Charbonneauhttps://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.pngStorm Charbonneau2021-03-02 17:14:422021-03-02 17:15:57Eyenovia Announces FDA Acceptance of the MydCombi NDA
Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
NEW YORK--(BUSINESS WIRE)--Jan. 26, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing…
https://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.png00sandboxhttps://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.pngsandbox2021-02-13 19:20:402021-02-13 19:32:03Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Topline Results Expected First Half of 2021 December 16, 2020…
https://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.png00sandboxhttps://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.pngsandbox2021-01-25 19:13:312021-02-13 23:45:05Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
December 29, 2020 07:00 AM Eastern Standard Time
NEW YORK--(BUSINESS WIRE)--Eyenovia,…
https://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.png00sandboxhttps://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.pngsandbox2021-01-25 19:12:092021-01-25 19:14:37Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis
NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will…
https://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.png00sandboxhttps://eyenovia.com/wp-content/uploads/2023/10/eyenovia-logo-340-156-300x138.pngsandbox2020-12-16 16:54:072020-12-16 18:12:31Eyenovia To Report Third Quarter 2020 Results
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
NewsEyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
NewsEYENOVIA TO REPORT FOURTH QUARTER AND FULL YEAR 2020 RESULTS ON THURSDAY, MARCH 25
NewsEyenovia to Participate in the 33rd Annual Roth Conference
NewsEyenovia Announces FDA Acceptance of the MydCombi NDA
NewsEyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
NewsEyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
NewsEyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis
NewsEyenovia To Report Third Quarter 2020 Results
News